QuDoS

Views & Analysis

Monitoring people who are on disease modifying drugs (DMDs) is paramount to providing safe, high-quality MS care.

Views & Analysis

Best healthcare professionals working in multiple sclerosis (MS) honoured QuDoS awards.

News

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.